445 related articles for article (PubMed ID: 29178957)
1. Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
Jacobs DM; Safir MC; Huang D; Minhaj F; Parker A; Rao GG
Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):76. PubMed ID: 29178957
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.
Lee GC; Burgess DS
Ann Clin Microbiol Antimicrob; 2012 Dec; 11():32. PubMed ID: 23234297
[TBL] [Abstract][Full Text] [Related]
3. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit.
Sbrana F; Malacarne P; Viaggi B; Costanzo S; Leonetti P; Leonildi A; Casini B; Tascini C; Menichetti F
Clin Infect Dis; 2013 Mar; 56(5):697-700. PubMed ID: 23155147
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Qureshi ZA; Paterson DL; Potoski BA; Kilayko MC; Sandovsky G; Sordillo E; Polsky B; Adams-Haduch JM; Doi Y
Antimicrob Agents Chemother; 2012 Apr; 56(4):2108-13. PubMed ID: 22252816
[TBL] [Abstract][Full Text] [Related]
5. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.
Medeiros GS; Rigatto MH; Falci DR; Zavascki AP
Int J Antimicrob Agents; 2019 Feb; 53(2):152-157. PubMed ID: 30722960
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.
Camargo JF; Simkins J; Beduschi T; Tekin A; Aragon L; Pérez-Cardona A; Prado CE; Morris MI; Abbo LM; Cantón R
Antimicrob Agents Chemother; 2015 Oct; 59(10):5903-8. PubMed ID: 26386029
[TBL] [Abstract][Full Text] [Related]
8.
Huang D; Yu B; Diep JK; Sharma R; Dudley M; Monteiro J; Kaye KS; Pogue JM; Abboud CS; Rao GG
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438930
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.
Satlin MJ; Kubin CJ; Blumenthal JS; Cohen AB; Furuya EY; Wilson SJ; Jenkins SG; Calfee DP
Antimicrob Agents Chemother; 2011 Dec; 55(12):5893-9. PubMed ID: 21968368
[TBL] [Abstract][Full Text] [Related]
10. Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda.
De Rosa FG; Corcione S; Cavallo R; Di Perri G; Bassetti M
Future Microbiol; 2015; 10(2):283-94. PubMed ID: 25689539
[TBL] [Abstract][Full Text] [Related]
11. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?
Daikos GL; Markogiannakis A
Clin Microbiol Infect; 2011 Aug; 17(8):1135-41. PubMed ID: 21635663
[TBL] [Abstract][Full Text] [Related]
12. Infections Caused by Carbapenemase-Producing Klebsiella pneumoniae: Microbiological Characteristics and Risk Factors.
Pan H; Lou Y; Zeng L; Wang L; Zhang J; Yu W; Qiu Y
Microb Drug Resist; 2019 Mar; 25(2):287-296. PubMed ID: 30810470
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
[TBL] [Abstract][Full Text] [Related]
14. [Controlling infection and spread of carbapenems-resistant Klebsiella pneumoniae among burn patients].
Huan J
Zhonghua Shao Shang Za Zhi; 2015 Feb; 31(1):5-8. PubMed ID: 25876631
[TBL] [Abstract][Full Text] [Related]
15. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.
Shields RK; Nguyen MH; Potoski BA; Press EG; Chen L; Kreiswirth BN; Clarke LG; Eschenauer GA; Clancy CJ
Antimicrob Agents Chemother; 2015 Mar; 59(3):1797-801. PubMed ID: 25534733
[TBL] [Abstract][Full Text] [Related]
16. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
[TBL] [Abstract][Full Text] [Related]
18. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.
Hirsch EB; Tam VH
J Antimicrob Chemother; 2010 Jun; 65(6):1119-25. PubMed ID: 20378670
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen.
Oliva A; Mascellino MT; Cipolla A; D'Abramo A; De Rosa A; Savinelli S; Ciardi MR; Mastroianni CM; Vullo V
Int J Infect Dis; 2015 Apr; 33():132-4. PubMed ID: 25597275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
